Libtayo ® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Regeneron (REGN) announced positive Phase 3 C-POST trial results for Libtayo (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) patients after surgery, demonstrating a 68% reduction in the risk of disease recurrence or death compared to placebo (p<0.0001). The study, presented at ASCO and published in the New England Journal of Medicine, also showed significant reductions in locoregional and distant recurrence risks, with regulatory applications submitted in the US and EU. These results position Libtayo as a potential new standard of care in the adjuvant setting for high-risk CSCC, particularly given negative results presented at ASCO for another PD-1 inhibitor in a similar setting.

Analysis

Regeneron Pharmaceuticals has reported highly compelling detailed results from its Phase 3 C-POST trial for Libtayo (cemiplimab) in the adjuvant treatment of high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery. The trial met its primary endpoint, demonstrating a statistically significant 68% reduction in the risk of disease recurrence or death compared to placebo (Hazard Ratio [HR]: 0.32; p<0.0001), with two-year disease-free survival (DFS) rates of 87% for Libtayo versus 64% for placebo. Importantly, Libtayo also achieved substantial reductions in the risk of locoregional recurrence (80%) and distant recurrence (65%). These findings, presented at the ASCO 2025 Annual Meeting and published in the New England Journal of Medicine, position Libtayo as the first immunotherapy to show such a benefit in this setting, especially noteworthy given the reported negative results for another PD-1 inhibitor at the same conference. An emerging overall survival (OS) benefit was also suggested (HR: 0.78), and efficacy was consistent regardless of PD-L1 expression levels. While adverse events (AEs) were more common with Libtayo, including Grade ≥3 AEs (24% vs. 14% for placebo) and treatment discontinuations due to AEs (10% vs. 2%), the safety profile appears manageable within the context of significant efficacy in a high-risk cancer population. Regulatory applications for this indication have been submitted in both the United States and the European Union, signaling a potential expansion of Libtayo's market and a new standard of care.

Key Decisions for Investors

• The strong efficacy data from the C-POST trial significantly enhances Libtayo's market potential in adjuvant high-risk CSCC, potentially leading to accelerated regulatory approvals and substantial revenue contribution for Regeneron.
• Investors should monitor the upcoming regulatory decisions from the FDA and EMA, as approvals would be key catalysts for Regeneron and solidify Libtayo's competitive advantage, especially given contrasting results from a competitor PD-1 inhibitor.
• Consider the favorable risk-benefit profile demonstrated, as the significant reduction in recurrence and death will likely outweigh the increased incidence of manageable adverse events, supporting strong physician adoption if approved.
• The consistent efficacy across PD-L1 expression levels broadens the addressable patient population for Libtayo, potentially simplifying treatment decisions and increasing its uptake in this indication.